MX2016013564A - Inhibidores heterociclicos de cinasas. - Google Patents
Inhibidores heterociclicos de cinasas.Info
- Publication number
- MX2016013564A MX2016013564A MX2016013564A MX2016013564A MX2016013564A MX 2016013564 A MX2016013564 A MX 2016013564A MX 2016013564 A MX2016013564 A MX 2016013564A MX 2016013564 A MX2016013564 A MX 2016013564A MX 2016013564 A MX2016013564 A MX 2016013564A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- heterocyclic kinase
- heterocyclic
- compounds
- stereoisomers
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000001900 immune effect Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/075560 WO2015157955A1 (en) | 2014-04-17 | 2014-04-17 | Heterocyclic btk inhibit ors |
| PCT/CN2015/076766 WO2015158283A1 (en) | 2014-04-17 | 2015-04-16 | Heterocyclic kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016013564A true MX2016013564A (es) | 2017-05-09 |
Family
ID=54323386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016013564A MX2016013564A (es) | 2014-04-17 | 2015-04-16 | Inhibidores heterociclicos de cinasas. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10280184B2 (enExample) |
| EP (1) | EP3131900A4 (enExample) |
| JP (1) | JP2017511365A (enExample) |
| CN (1) | CN106459045A (enExample) |
| AU (1) | AU2015246482A1 (enExample) |
| BR (1) | BR112016024057A2 (enExample) |
| CA (1) | CA2946036A1 (enExample) |
| MX (1) | MX2016013564A (enExample) |
| WO (2) | WO2015157955A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9932340B2 (en) * | 2014-12-18 | 2018-04-03 | Abbvie Inc. | Substituted indoles |
| EP3294737A4 (en) * | 2015-05-12 | 2018-10-03 | Kalyra Pharmaceuticals, Inc. | Bicyclic compounds |
| KR20180094906A (ko) * | 2015-11-20 | 2018-08-24 | 밍사이트 파마슈티칼스, 인크. | 자가면역 질환의 치료 |
| US11352339B2 (en) | 2016-03-24 | 2022-06-07 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as DUB inhibitors |
| GB201616511D0 (en) * | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| WO2018098491A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| JP7105797B2 (ja) | 2016-11-28 | 2022-07-25 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | 化合物及びその使用方法 |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| JP7219902B2 (ja) * | 2017-03-22 | 2023-02-09 | スジョウ・バイジブゴン・ファーマスーティカル・テクノロジー・カンパニー・リミテッド | ブルトン型チロシンキナーゼ阻害剤 |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| CR20230030A (es) | 2018-02-27 | 2023-03-10 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441) |
| MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
| TWI831786B (zh) | 2018-05-30 | 2024-02-11 | 美商普雷西斯精密藥品公司 | 離子通道調節劑 |
| MX2021000116A (es) * | 2018-07-05 | 2021-03-29 | Incyte Corp | Derivados de pirazina fusionados como inhibidores de a2a/a2b. |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| EP4023647B1 (en) * | 2019-08-30 | 2025-04-09 | TSD Life Sciences Co., Ltd. | Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| EP3915990A1 (en) | 2020-05-26 | 2021-12-01 | Centre National de la Recherche Scientifique | 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer |
| EP4157848A4 (en) * | 2020-06-01 | 2024-07-17 | Nanjing Ruijie Pharma Co., Ltd. | COMPOUNDS AND THEIR USES AS SPLEEN TYROSINE KINASE INHIBITORS |
| WO2021249417A1 (zh) * | 2020-06-09 | 2021-12-16 | 赛诺哈勃药业（成都）有限公司 | 杂环化合物及其衍生物 |
| GB202014114D0 (en) * | 2020-09-08 | 2020-10-21 | Synairgen Res Ltd | Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid |
| EP4244223A1 (en) * | 2020-11-13 | 2023-09-20 | Biogen MA Inc. | Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors |
| JP2025515728A (ja) * | 2022-05-10 | 2025-05-20 | バイオジェン・エムエイ・インコーポレイテッド | Ｎ－メチル－Ｎ－（（１ｓ，３ｓ）－３－メチル－３－（（６－（１－メチル－１Ｈ－ピラゾール－４－イル）ピラゾロ［１，５－ａ］ピラジン－４－イル）オキシ）シクロブチル）アクリルアミドの結晶多形 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060492A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
| OA12552A (en) * | 2001-03-09 | 2006-06-06 | Pfizer Prod Inc | Triazolopyridines as anti-inflammatory agents. |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| WO2005085252A1 (en) * | 2004-03-04 | 2005-09-15 | Biofocus Discovery Limited | Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases |
| DE102004030782A1 (de) * | 2004-06-25 | 2006-01-19 | Fev Motorentechnik Gmbh | Fahrzeug-Steuergerät mit einem neuronalen Netz |
| DE602005023333D1 (de) * | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
| WO2007032936A2 (en) | 2005-09-09 | 2007-03-22 | Schering Corporation | Azafused cyclin dependent kinase inhibitors |
| DE102007032349A1 (de) * | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| PE20091074A1 (es) | 2007-12-13 | 2009-07-26 | Bayer Healthcare Ag | Triazolotriazinas y triazolopirazinas y su uso |
| CN101952283B (zh) | 2007-12-14 | 2013-04-17 | 霍夫曼-拉罗奇有限公司 | 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物 |
| ES2552681T3 (es) | 2008-07-15 | 2015-12-01 | F. Hoffmann-La Roche Ag | Nuevas fenil-imidazopiridinas y piridazinas |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| WO2010068258A1 (en) | 2008-12-08 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Imidazopyrazine syk inhibitors |
| WO2010068806A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
| WO2010068810A2 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| EP2343294A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| MX350010B (es) | 2010-03-11 | 2017-08-23 | Gilead Connecticut Inc | Inhibidores syk de imidazopiridinas. |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| US20140187548A1 (en) | 2010-12-17 | 2014-07-03 | Bayer Intellectual Property Gmbh | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| JP5951750B2 (ja) * | 2011-04-06 | 2016-07-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリジン類およびその中間体 |
| WO2012163724A1 (en) * | 2011-05-31 | 2012-12-06 | F. Hoffmann-La Roche Ag | Triazolopyridine compounds |
| RU2662443C2 (ru) | 2011-11-01 | 2018-07-26 | Ф. Хоффманн-Ля Рош Аг | Имидазопиридазины |
| US8722676B2 (en) | 2011-11-03 | 2014-05-13 | Genentech, Inc. | Bicyclic piperazine compounds |
| CA2854603A1 (en) * | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
-
2014
- 2014-04-17 WO PCT/CN2014/075560 patent/WO2015157955A1/en not_active Ceased
-
2015
- 2015-04-16 US US15/304,131 patent/US10280184B2/en active Active
- 2015-04-16 AU AU2015246482A patent/AU2015246482A1/en not_active Abandoned
- 2015-04-16 BR BR112016024057A patent/BR112016024057A2/pt not_active Application Discontinuation
- 2015-04-16 WO PCT/CN2015/076766 patent/WO2015158283A1/en not_active Ceased
- 2015-04-16 MX MX2016013564A patent/MX2016013564A/es unknown
- 2015-04-16 JP JP2016562835A patent/JP2017511365A/ja active Pending
- 2015-04-16 CN CN201580031633.1A patent/CN106459045A/zh active Pending
- 2015-04-16 CA CA2946036A patent/CA2946036A1/en not_active Abandoned
- 2015-04-16 EP EP15780191.1A patent/EP3131900A4/en not_active Withdrawn
-
2018
- 2018-12-21 US US16/230,408 patent/US20190135836A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015158283A1 (en) | 2015-10-22 |
| EP3131900A4 (en) | 2017-11-15 |
| WO2015157955A1 (en) | 2015-10-22 |
| CN106459045A (zh) | 2017-02-22 |
| JP2017511365A (ja) | 2017-04-20 |
| AU2015246482A1 (en) | 2016-10-27 |
| US20170114077A1 (en) | 2017-04-27 |
| BR112016024057A2 (pt) | 2017-08-15 |
| US10280184B2 (en) | 2019-05-07 |
| CA2946036A1 (en) | 2015-10-22 |
| EP3131900A1 (en) | 2017-02-22 |
| US20190135836A1 (en) | 2019-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016013564A (es) | Inhibidores heterociclicos de cinasas. | |
| NZ754039A (en) | Primary carboxamides as btk inhibitors | |
| PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
| MX2020003224A (es) | Moduladores de receptor nuclear. | |
| PH12018500343A1 (en) | Heterocyclic amides as kinase inhibitors | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| TW201613872A (en) | IRAK4 inhibiting agents | |
| MA39749A (fr) | Dérivés de pipéridine-dione | |
| PH12017500416A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| NZ716392A (en) | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors | |
| TW201613886A (en) | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones | |
| PH12017501523A1 (en) | Selective bace1 inhibitors | |
| PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
| MX2017007607A (es) | Inhibidores de necrosis celular y metodos relacionados. | |
| PH12019501022A1 (en) | Pyrazolopyrimidine compounds and methods of use thereof | |
| MA40250A (fr) | Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k | |
| TW201612165A (en) | Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound | |
| MX2015013414A (es) | N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa. | |
| LT3709996T (lt) | Kumarino darinys, skirtas ląstelių proliferacijos sutrikimo terapijai arba profilaktikai | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| MX2019002065A (es) | Derivado de triazolopirazinona util como un inhibidor de pde1 humana. | |
| EA201791596A1 (ru) | Пиразоловые соединения | |
| HK40042815A (en) | Heterocyclic compounds as kinase inhibitors |